Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth

AbbVie has transformed its oncology franchise beyond its original blood-cancer duo, adding solid-tumor drugs Epkinly, Elahere and internally developed Emrelis, with oncology sales accounting for more than 11% of total revenues in the first nine months of 2025 as company revenue grew 3% year‑over‑year. The gains reflect a mix of acquisitions, collaborations and internal R&D—rising Venclexta sales and new product launches have largely offset declines in Imbruvica—while a push into antibody‑drug conjugates (pivekimab sunirine filing for BPDCN, Temab‑A development) and a late‑stage BCMA x CD3 bispecific (ABBV‑383) materially diversifies the pipeline. AbbVie faces strong competition from entrenched oncology players (AstraZeneca, Merck, Pfizer) but trades at a slight forward P/E discount to the industry (15.87x vs 16.31x) even as EPS estimates for 2025–26 have been trimmed recently, leaving near‑term valuation upside contingent on regulatory and commercial progress.

Analysis

AbbVie has expanded its oncology franchise beyond the original blood-cancer duo to include Epkinly, Elahere and internally developed Emrelis, with oncology sales representing more than 11% of total revenues in the first nine months of 2025 while company revenue grew 3% year‑over‑year. Rising Venclexta sales and revenue from newer launches have more than offset declines in Imbruvica, which the article attributes to competitive pressure from novel oral therapies.

The company is prioritizing antibody‑drug conjugates (ADCs) and other advanced modalities: pivekimab sunirine is under FDA review for BPDCN and would join Elahere and Emrelis if approved; Temab‑A (ABBV‑400) is in a late‑stage metastatic colorectal study and mid‑stage studies in gastroesophageal and lung cancers. AbbVie is also developing etentamig/ABBV‑383 (a BCMA x CD3 bispecific) in late‑stage relapsed/refractory multiple myeloma and pursuing label expansions, yielding multiple binary regulatory and clinical catalysts.

AbbVie trades at a modest forward P/E discount to the industry (15.87x vs. 16.31x) and above its five‑year mean (13.44), and shares have outperformed the industry year‑to‑date, but EPS estimates for 2025–26 have been trimmed recently and Zacks assigns a Hold (Rank #3). Competitive dynamics with AstraZeneca, Merck and Pfizer—each with larger oncology revenue concentrations—heighten execution risk and make near‑term upside contingent on successful approvals, trial readouts and commercial uptake.

Key Decisions for Investors

• Adopt a catalyst‑driven stance: consider modest additions or maintaining a small position ahead of the pivekimab FDA decision and key readouts for Temab‑A and ABBV‑383, but avoid large scale increases until positive regulatory/commercial data materialize
• Monitor product revenue trends for Epkinly, Elahere, Emrelis and Venclexta versus continuing Imbruvica decline as the primary indicator of durable oncology replacement; be prepared to trim or hedge if net oncology contribution does not sustain organic growth
• Use the slight forward P/E discount (15.87x vs 16.31x) and recent EPS downgrades as signals to wait for de‑risking events before re‑rating positions, and consider relative exposure to AZN or MRK for broader oncology diversification
• Watch consensus EPS revisions and company guidance closely; implement downside protection if estimates continue to move lower or if trial/regulatory timelines slip